All In Biotech

Drug Trial Radar · NCT07750158

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Dec 18, 2026

Primary completion

Apr 5, 2030

Study completion Apr 5, 2030

Sponsor

Lead sponsor
ExelixisIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.

Conditions

  • Colorectal Cancer

Interventions

  • ZanzalintinibDrug

    Oral tablets administered once daily.

  • Pembrolizumab (+) Berahyaluronidase alfaBiological

    Pembrolizumab + berahyaluronidase alfa fixed-dose combination administered via subcutaneous (SC) injection once every 3 weeks (Q3W).

  • PlaceboDrug

    Placebo to match zanzalintinib oral tablets administered once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the InvestigatorTime frame: Up to 24 months
  2. DFS in Zanzalintinib Monotherapy Versus Placebo as Assessed by the InvestigatorTime frame: Up to 24 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center

    Fort Lauderdale, Florida · Recruiting

  • Orlando Health Cancer Institute

    Lake Mary, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Low Country Cancer Care

    Savannah, Georgia · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Council Bluffs

    Council Bluffs, Iowa · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island

    Grand Island, Nebraska · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional

    Grand Island, Nebraska · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Methodist

    Omaha, Nebraska · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan

    Omaha, Nebraska · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy

    Omaha, Nebraska · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Papillion

    Papillion, Nebraska · Recruiting

  • Astera Cancer Care

    Bridgewater, New Jersey · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • Astera Cancer Care

    Edison, New Jersey · Recruiting

  • Astera Cancer Care

    Monroe, New Jersey · Recruiting

  • Astera Cancer Care

    Somerset, New Jersey · Recruiting

  • Astera Cancer Care

    Toms River, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.